Results 241 to 250 of about 592,070 (354)

Sugar Control of the Plant Cell Cycle: Differential Regulation ofArabidopsisD-Type Cyclin Gene Expression

, 2000
Catherine Riou, Margit Menges, John Healy, J. A. H. Murray   +3 more
openalex   +2 more sources

Cyclin E and p27 protein content in human renal cell carcinoma: Clinical outcome and associations with cyclin D [PDF]

, 2002
Ylva Hedberg, Estela Davoodi, Börje Ljungberg, Göran Roos, Göran Landberg   +4 more
openalex   +1 more source

Unveiling the complexity of cellular senescence in cancers: From mechanism to therapeutic opportunities

BMEMat, EarlyView.
This review highlights the complex roles of cellular senescence in cancer progression and suppression, discusses the mechanisms and regulatory pathways involved, and evaluates the efficacy of the “One‐Two punch” sequential treatment approach while addressing emerging challenges in this novel therapeutic strategy.
Qiuming Pan, Ye Zhu, Zhi Ye, Huayang Zhang, Junxi Wang, Guozhong Yi, Zhiyong Li, Rongyang Xu, Luyao Wang, Zhenzhen Wu, Songtao Qi, Guanglong Huang, Shanqiang Qu   +12 more
wiley   +1 more source

The Drosophila Cyclin D-Cdk4 complex promotes cellular growth

, 2000
Sanjeev A. Datar
openalex   +2 more sources

Development of mice expressing a single D-type cyclin [PDF]

, 2002
Maria A. Ciemerych, Anna Marie Kenney, Ewa Sicińska, Ilona Kalaszczyńska, Roderick T. Bronson, David H. Rowitch, Humphrey Gardner, Piotr Siciński   +7 more
openalex   +1 more source

Genetic alterations of Cyclin D-CDK4/6-INK4-RB pathway in prostate cancer. [PDF]

Mol Biol Rep
Sivoňová MK, Híveš M, Kliment J, Dušenka R, Grendár M, Evin D, Kaplán P, Brožová MK, Vilčková M, Vondrák A, Jurečeková J.   +10 more
europepmc   +1 more source

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu   +18 more
wiley   +1 more source

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications, EarlyView.
Abstract Background The combined use of anti‐programmed cell death protein 1 (PD‐1)/anti‐cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and ...
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic, Sajeve S. Thomas, William R. Robinson III, Hye Sung Kim, Liam Il‐Young Chung, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock   +16 more
wiley   +1 more source

A non-canonical role of somatic Cyclin D/CYD-1 in oogenesis and in maintenance of reproductive fidelity, dependent on the FOXO/DAF-16 activation state. [PDF]

PLoS Genet
Rautela U, Sarkar GC, Chaudhary A, Chatterjee D, Rosh M, Arimbasseri AG, Mukhopadhyay A.   +6 more
europepmc   +1 more source

Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth. [PDF]

Theranostics, 2020
Bouclier C, Simon M, Laconde G, Pellerano M, Diot S, Lantuejoul S, Busser B, Vanwonterghem L, Vollaire J, Josserand V, Legrand B, Coll JL, Amblard M, Hurbin A, Morris MC.   +14 more
europepmc   +1 more source